{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:16:17Z","timestamp":1793128577650,"version":"4.5.0"},"reference-count":52,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["0134-00072B"],"award-info":[{"award-number":["0134-00072B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Research Council at Herlev and Gentofte Hospital","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Fonden til fremme af klinisk cancerforskning","award":["RL-WSDOCS.FID1280670"],"award-info":[{"award-number":["RL-WSDOCS.FID1280670"]}]},{"name":"T\u00f8mrermester J\u00f8rgen Holm og hustru Elisa f. Hansens Mindelegat","award":["20039"],"award-info":[{"award-number":["20039"]}]},{"name":"Danish Health Authority","award":["4-1612-236\/8"],"award-info":[{"award-number":["4-1612-236\/8"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,11,6]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is associated with very poor survival, making it the third and fourth leading cause of all cancer-related deaths in the USA and European Union, respectively. The tumor microenvironment (TME) in PDAC is highly immunosuppressive and desmoplastic, which could explain the limited therapeutic effect of immunotherapy in PDAC. One of the key molecules that contributes to immunosuppression and fibrosis is transforming growth factor-\u03b2 (TGF\u03b2). The aim of this study was to target the immunosuppressive and fibrotic TME in PDAC using a novel immune modulatory vaccine with TGF\u03b2-derived peptides in a murine model of pancreatic cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>C57BL\/6 mice were subcutaneously inoculated with Pan02 PDAC cells. Mice were treated with TGF\u03b21-derived peptides (major histocompatibility complex (MHC)-I and MHC-II-restricted) adjuvanted with Montanide ISA 51VG. The presence of treatment-induced TGF\u03b2-specific T cells was assessed by ELISpot (enzyme-linked immunospot). Changes in the immune infiltration and gene expression profile in tumor samples were characterized by flow cytometry, reverse transcription-quantitative PCR (RT-qPCR), and bulk RNA sequencing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Treatment with immunogenic TGF\u03b2-derived peptides was safe and controlled tumor growth in Pan02 tumor-bearing mice. Enlargement of tumor-draining lymph nodes in vaccinated mice positively correlated to the control of tumor growth. Analysis of immune infiltration and gene expression in Pan02 tumors revealed that TGF\u03b2-derived peptide vaccine increased the infiltration of CD8<jats:sup>+<\/jats:sup> T cells and the intratumoral M1\/M2 macrophage ratio, it increased the expression of genes involved in immune activation and immune response to tumors, and it reduced the expression of myofibroblast-like cancer-associated fibroblast (CAF)-related genes and genes encoding fibroblast-derived collagens. Finally, we confirmed that TGF\u03b2-derived peptide vaccine actively modulated the TME, as the ability of T cells to proliferate was restored when exposed to tumor-conditioned media from vaccinated mice compared with media from untreated mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study demonstrates the antitumor activity of TGF\u03b2-derived multipeptide vaccination in a murine tumor model of PDAC. The data suggest that the vaccine targets immunosuppression and fibrosis in the TME by polarizing the cellular composition towards a more pro-inflammatory phenotype. Our findings support the feasibility and potential of TGF\u03b2-derived peptide vaccination as a novel immunotherapeutic approach to target immunosuppression in the TME.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-005491","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:30:38Z","timestamp":1670319038000},"page":"e005491","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["TGF\u03b2-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-9184","authenticated-orcid":false,"given":"Maria","family":"Perez-Penco","sequence":"first","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine Emilie","family":"Weis-Banke","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimilia","family":"Schina","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majken","family":"Siersb\u00e6k","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie Linder","family":"H\u00fcbbe","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia Aaboe","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Lecoq","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"},{"name":"IO Biotech ApS, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Lara de la Torre","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone Kloch","family":"Bendtsen","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Martinenaite","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"},{"name":"IO Biotech ApS, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Orebo","family":"Holmstr\u00f6m","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Hargb\u00f8l","family":"Madsen","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"},{"name":"Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-9752","authenticated-orcid":false,"given":"Marco","family":"Donia","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"\u00d8dum","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Gr\u00f8ntved","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-9605","authenticated-orcid":false,"given":"Mads Hald","family":"Andersen","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"},{"name":"Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"2025100306274171000_10.12.e005491.1","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v27.i27.4298","article-title":"Pancreatic cancer: a review of epidemiology, trend, and risk factors","volume":"27","author":"Hu","year":"2021","journal-title":"World J Gastroenterol"},{"key":"2025100306274171000_10.12.e005491.2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.annonc.2021.12.007","article-title":"European cancer mortality predictions for the year 2022 with focus on ovarian cancer","volume":"33","author":"Dalmartello","year":"2022","journal-title":"Ann Oncol"},{"key":"2025100306274171000_10.12.e005491.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59121-0"},{"key":"2025100306274171000_10.12.e005491.4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4251\/wjgo.v13.i6.472","article-title":"Current controversies and advances in the management of pancreatic adenocarcinoma","volume":"13","author":"Zeeshan","year":"2021","journal-title":"World J Gastrointest Oncol"},{"key":"2025100306274171000_10.12.e005491.5","doi-asserted-by":"crossref","unstructured":"Chen IM , Johansen JS , Theile S . Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC). J Clin Oncol 2022;1.","DOI":"10.1200\/JCO.21.02511"},{"key":"2025100306274171000_10.12.e005491.6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164138","article-title":"Pancreatic cancer and immunotherapy: a clinical overview","volume":"13","author":"Timmer","year":"2021","journal-title":"Cancers"},{"key":"2025100306274171000_10.12.e005491.7","first-page":"6","article-title":"Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects","volume":"6","author":"Li","year":"2020","journal-title":"Chronic Dis Transl Med"},{"key":"2025100306274171000_10.12.e005491.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.024"},{"key":"2025100306274171000_10.12.e005491.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0363-5"},{"key":"2025100306274171000_10.12.e005491.10","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.3390\/cancers13205086","article-title":"TGF\u03b2 signaling in the pancreatic tumor microenvironment","volume":"13","author":"Principe","year":"2021","journal-title":"Cancers"},{"key":"2025100306274171000_10.12.e005491.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02974-x"},{"key":"2025100306274171000_10.12.e005491.12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00281-016-0593-x","article-title":"Anti-regulatory T cells","volume":"39","author":"Andersen","year":"2017","journal-title":"Semin Immunopathol"},{"key":"2025100306274171000_10.12.e005491.13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3607"},{"key":"2025100306274171000_10.12.e005491.14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00281-018-0695-8","article-title":"The T-win\u00ae technology: immune-modulating vaccines","volume":"41","author":"Andersen","year":"2019","journal-title":"Semin Immunopathol"},{"key":"2025100306274171000_10.12.e005491.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-288498"},{"key":"2025100306274171000_10.12.e005491.16","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23991"},{"key":"2025100306274171000_10.12.e005491.17","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s00262-019-02425-6","article-title":"Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope","volume":"68","author":"Martinenaite","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2025100306274171000_10.12.e005491.18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1771142","article-title":"The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines","volume":"9","author":"Weis-Banke","year":"2020","journal-title":"Oncoimmunology"},{"key":"2025100306274171000_10.12.e005491.19","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2026020","article-title":"Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment","volume":"11","author":"Bendtsen","year":"2022","journal-title":"Oncoimmunology"},{"key":"2025100306274171000_10.12.e005491.20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000605"},{"key":"2025100306274171000_10.12.e005491.21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0280"},{"key":"2025100306274171000_10.12.e005491.22","doi-asserted-by":"crossref","unstructured":"Kjeldsen JW , Lorentzen L , Cathrine HA . An immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma: a phase 1\/2 trial. Nat Med 2021.","DOI":"10.1038\/s41591-021-01544-x"},{"key":"2025100306274171000_10.12.e005491.23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41423-020-00593-5","article-title":"Cytotoxic T cells isolated from healthy donors and cancer patients kill TGF\u03b2-expressing cancer cells in a TGF\u03b2-dependent manner","volume":"18","author":"Holmstr\u00f6m","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2025100306274171000_10.12.e005491.24","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/s41423-021-00770-0","article-title":"Characterization of TGF\u03b2-specific CD4+T cells through the modulation of TGF\u03b2 expression in malignant myeloid cells","volume":"18","author":"Mortensen","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2025100306274171000_10.12.e005491.25","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btv639"},{"key":"2025100306274171000_10.12.e005491.26","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41388-021-02170-0","article-title":"Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment","volume":"41","author":"Fj\u00e6stad","year":"2022","journal-title":"Oncogene"},{"key":"2025100306274171000_10.12.e005491.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04080-3"},{"key":"2025100306274171000_10.12.e005491.28","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1404-8"},{"key":"2025100306274171000_10.12.e005491.29","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337"},{"key":"2025100306274171000_10.12.e005491.30","doi-asserted-by":"publisher","DOI":"10.1038\/srep41926"},{"key":"2025100306274171000_10.12.e005491.31","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1462431"},{"key":"2025100306274171000_10.12.e005491.32","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318189f13c"},{"key":"2025100306274171000_10.12.e005491.33","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/cancers13030440","article-title":"Preclinical models of pancreatic ductal adenocarcinoma and their utility in immunotherapy studies","volume":"13","author":"Pham","year":"2021","journal-title":"Cancers"},{"key":"2025100306274171000_10.12.e005491.34","unstructured":"Urs S . Pan02: a murine model of pancreatic cancer, 2019. Labcorp Drug Dev. Available: https:\/\/drugdevelopment.labcorp.com\/industry-solutions\/oncology\/preclinical\/tumor-spotlights\/pan02-a-murine-model-of-pancreatic-cancer.html"},{"key":"2025100306274171000_10.12.e005491.35","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0778-0"},{"key":"2025100306274171000_10.12.e005491.36","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73"},{"key":"2025100306274171000_10.12.e005491.37","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.trecan.2019.09.010","article-title":"Caf subpopulations: a new reservoir of stromal targets in pancreatic cancer","volume":"5","author":"Pereira","year":"2019","journal-title":"Trends Cancer"},{"key":"2025100306274171000_10.12.e005491.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13889-6"},{"key":"2025100306274171000_10.12.e005491.39","doi-asserted-by":"crossref","first-page":"100022","DOI":"10.1074\/mcp.R120.002309","article-title":"The peptide vaccine of the future","volume":"20","author":"Nelde","year":"2021","journal-title":"Mol Cell Proteomics"},{"key":"2025100306274171000_10.12.e005491.40","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0105"},{"key":"2025100306274171000_10.12.e005491.41","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021907"},{"key":"2025100306274171000_10.12.e005491.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2017.12.009"},{"key":"2025100306274171000_10.12.e005491.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-016-0009-6"},{"key":"2025100306274171000_10.12.e005491.44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.771488","article-title":"The scavenger receptor MARCO expressed by tumor-associated macrophages are highly associated with poor pancreatic cancer prognosis","volume":"11","author":"Shi","year":"2021","journal-title":"Front Oncol"},{"key":"2025100306274171000_10.12.e005491.45","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0094"},{"key":"2025100306274171000_10.12.e005491.46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.791453","article-title":"Immune modulatory properties of collagen in cancer","volume":"12","author":"R\u00f8mer","year":"2021","journal-title":"Front Immunol"},{"key":"2025100306274171000_10.12.e005491.47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1085147","article-title":"Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma","volume":"5","author":"Castino","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100306274171000_10.12.e005491.48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.18632\/oncotarget.6345","article-title":"Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes","volume":"7","author":"Craven","year":"2016","journal-title":"Oncotarget"},{"key":"2025100306274171000_10.12.e005491.49","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3233"},{"key":"2025100306274171000_10.12.e005491.50","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","article-title":"Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer","volume":"119","author":"Melisi","year":"2018","journal-title":"Br J Cancer"},{"key":"2025100306274171000_10.12.e005491.51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/9749363","article-title":"Development of peptide-based vaccines for cancer","volume":"2022","author":"Abd-Aziz","year":"2022","journal-title":"J Oncol"},{"key":"2025100306274171000_10.12.e005491.52","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-021-00728-9"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:27:52Z","timestamp":1759498072000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":52,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,6]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/jitc-2022-005491"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005491","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}